{
  "protocolSection": {
    "identificationModule": {
      "properties": "{{\n  \"identificationModule\": {\n    \"nctId\": \"NCT02951156\",\n    \"orgStudyIdInfo\": {\n      \"id\": \"B9991015\",\n      \"type\": null,\n      \"link\": null\n    },\n    \"secondaryIdInfos\": [],\n    \"organization\": {\n      \"fullName\": \"Pfizer\",\n      \"class\": \"INDUSTRY\"\n    },\n    \"briefTitle\": \"A Phase Ib/III Randomized Study of Avelumab in Combination with Utomilumab (PF-05082566), Azacitidine, Bendamustine, and/or Rituximab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma\",\n    \"officialTitle\": \"A Phase Ib/III Randomized Study of Avelumab in Combination with Utomilumab (PF-05082566), Azacitidine, Bendamustine, and/or Rituximab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma\",\n    \"acronym\": \"JAVELIN DLBCL\"\n  }\n}}"
    },
    "descriptionModule": {
      "briefSummary": "This was a phase Ib study investigating avelumab (an anti-PD-L1 antibody) in combination with other agents in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study evaluated three combination regimens: avelumab with utomilumab and rituximab (arm A), avelumab with utomilumab and azacitidine (arm B), and avelumab with bendamustine and rituximab (arm C). The primary endpoints were dose-limiting toxicities and objective response rate. The study was designed to assess whether these combination therapies could augment and sustain the antitumor immunity of avelumab in relapsed/refractory DLBCL.",
      "detailedDescription": "JAVELIN DLBCL (NCT02951156) was a multicenter, randomized, open-label, seamless two-component (phase Ib planned to be followed by phase III), parallel-arm study of avelumab in various combinations for the treatment of relapsed/refractory DLBCL. Based on preclinical and clinical data suggesting potential synergy between PD-L1 inhibition and various immunomodulatory agents, three combination regimens were investigated. Arm A combined avelumab with utomilumab (an IgG2 4-1BB agonist) and rituximab, based on evidence that 4-1BB agonism and PD-L1 antagonism may be synergistic and that anti-4-1BB agonist mAbs can enhance rituximab's anti-lymphoma activity. Arm B combined avelumab with utomilumab and azacitidine, based on evidence that epigenetic priming by azacitidine might sensitize cancer cells to PD-1/PD-L1 axis blockade. Arm C combined avelumab with bendamustine and rituximab, given that bendamustine and rituximab is recommended for relapsed/refractory DLBCL. Key eligibility criteria included histologically confirmed DLBCL in patients at least 18 years of age with relapsed/refractory disease following two or more and up to four lines of rituximab-based multiagent chemotherapy. Patients were randomized 1:1:1 to the three treatment arms. Avelumab 10 mg/kg was administered intravenously every 2 weeks in all arms. Primary endpoints were dose-limiting toxicities and objective response assessed by investigator per Lugano Response Classification criteria. Secondary endpoints included PD-L1 expression, minimal residual disease, duration of response, time to tumor response, disease control, progression-free survival, overall survival, and safety. The study also included comprehensive biomarker analyses including cell of origin assessment, immunohistochemical analyses for PD-L1, CD4, CD8, CD68, and 4-1BB/CD137, and minimal residual disease assessment using serial blood samples. The phase Ib component was designed to determine the most active treatment regimen to advance to a planned phase III component; however, due to insufficient antitumor activity in arms A and B and infeasibility of expanding arm C, the study was discontinued before initiation of the phase III component."
    },
    "conditionsModule": {
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "Relapsed Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "keywords": [
        "Diffuse Large B-Cell Lymphoma",
        "DLBCL",
        "Relapsed/Refractory DLBCL",
        "Avelumab",
        "PD-L1 Inhibitor",
        "Anti-PD-L1 Antibody",
        "Utomilumab",
        "4-1BB Agonist",
        "Rituximab",
        "Azacitidine",
        "Bendamustine",
        "Immunotherapy",
        "Checkpoint Inhibitor",
        "Combination Therapy",
        "B-Cell Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Relapsed Lymphoma",
        "Refractory Lymphoma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "patientRegistry": false,
      "phases": [
        "PHASE1",
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "This was a multicenter, randomized, open-label, seamless two-component (phase Ib planned to be followed by phase III), parallel-arm study. Patients were randomized 1:1:1 to receive avelumab in combination with utomilumab and rituximab (arm A), in combination with utomilumab and azacitidine (arm B), or in combination with bendamustine and rituximab (arm C).",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE",
          "maskingDescription": "This was an open-label study with no masking."
        }
      },
      "enrollmentInfo": {
        "count": 29,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Arm A: Avelumab + Utomilumab + Rituximab",
          "type": "EXPERIMENTAL",
          "description": "Patients received avelumab 10 mg/kg intravenously every 2 weeks, utomilumab 100 mg fixed dose intravenously (on day 2 of cycles 1 and 2, then on day 1 of cycle 3 and subsequent cycles if well-tolerated), and rituximab 375 mg/m2 intravenously on day 1 of each cycle for a maximum of 8 cycles.",
          "interventionNames": [
            "BIOLOGICAL: Avelumab",
            "BIOLOGICAL: Utomilumab",
            "BIOLOGICAL: Rituximab"
          ]
        },
        {
          "label": "Arm B: Avelumab + Utomilumab + Azacitidine",
          "type": "EXPERIMENTAL",
          "description": "Patients received avelumab 10 mg/kg intravenously every 2 weeks, utomilumab 100 mg fixed dose intravenously (on day 2 of cycles 1 and 2, then on day 1 of cycle 3 and subsequent cycles if well-tolerated), and azacitidine 40 mg/m2 subcutaneously on days 1 to 5 of each cycle.",
          "interventionNames": [
            "BIOLOGICAL: Avelumab",
            "BIOLOGICAL: Utomilumab",
            "DRUG: Azacitidine"
          ]
        },
        {
          "label": "Arm C: Avelumab + Bendamustine + Rituximab",
          "type": "EXPERIMENTAL",
          "description": "Patients received avelumab 10 mg/kg intravenously every 2 weeks, bendamustine 90 mg/m2 intravenously on days 2 and 3 of cycles 1 and 2 (if well-tolerated, on day 1 and day 2 in cycle 3 and subsequent cycles) for a maximum of 6 cycles, and rituximab 375 mg/m2 intravenously on day 1 of each cycle for a maximum of 8 cycles.",
          "interventionNames": [
            "BIOLOGICAL: Avelumab",
            "DRUG: Bendamustine",
            "BIOLOGICAL: Rituximab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Avelumab",
          "description": "Human anti-programmed death ligand 1 (anti-PD-L1) IgG1 monoclonal antibody administered at 10 mg/kg intravenously every 2 weeks with mandatory premedication (antihistamine and acetaminophen 30-60 min before each dose). Administered at least 1 hour after the end of other agents in the combination.",
          "armGroupLabels": [
            "Arm A: Avelumab + Utomilumab + Rituximab",
            "Arm B: Avelumab + Utomilumab + Azacitidine",
            "Arm C: Avelumab + Bendamustine + Rituximab"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Utomilumab",
          "description": "IgG2 4-1BB (CD137) agonist monoclonal antibody administered at 100 mg fixed dose intravenously on day 2 of each cycle in cycles 1 and 2, or if well-tolerated, on day 1 in cycle 3 and all subsequent cycles. Administered at least 1 hour after rituximab infusion was complete.",
          "armGroupLabels": [
            "Arm A: Avelumab + Utomilumab + Rituximab",
            "Arm B: Avelumab + Utomilumab + Azacitidine"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Rituximab",
          "description": "Anti-CD20 monoclonal antibody administered at 375 mg/m2 intravenously on day 1 of each cycle for a maximum of 8 cycles.",
          "armGroupLabels": [
            "Arm A: Avelumab + Utomilumab + Rituximab",
            "Arm C: Avelumab + Bendamustine + Rituximab"
          ]
        },
        {
          "type": "DRUG",
          "name": "Azacitidine",
          "description": "DNA methyltransferase inhibitor administered at 40 mg/m2 subcutaneously on days 1 to 5 of each cycle until the patient was no longer receiving clinical benefit.",
          "armGroupLabels": [
            "Arm B: Avelumab + Utomilumab + Azacitidine"
          ]
        },
        {
          "type": "DRUG",
          "name": "Bendamustine",
          "description": "Chemotherapy agent administered at 90 mg/m2 intravenously on days 2 and 3 of cycles 1 and 2. If well-tolerated, administered on day 1 and day 2 in cycle 3 and all subsequent cycles for a maximum of 6 cycles.",
          "armGroupLabels": [
            "Arm C: Avelumab + Bendamustine + Rituximab"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Dose-limiting toxicities (DLTs)",
          "description": "Dose-limiting toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and summarized by number and percentage of patients with DLTs, treatment group, primary system organ class (SOC), and preferred term (PT).",
          "timeFrame": "During the DLT assessment period (cycles 1 and 2)"
        },
        {
          "measure": "Objective response (OR)",
          "description": "Objective response assessed by investigator per Lugano Response Classification criteria. Objective response rate (ORR) was estimated by dividing the number of patients with OR (complete response [CR] or partial response [PR]) by the number of patients randomized to the respective treatment arm.",
          "timeFrame": "From randomization until disease progression or end of study (approximately up to 2 years)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "PD-L1 expression levels",
          "description": "PD-L1 expression levels in tumor cells and cells of the tumor microenvironment at baseline, assessed by immunohistochemical analysis using SP263 (Ventana).",
          "timeFrame": "Baseline"
        },
        {
          "measure": "Minimal residual disease (MRD)",
          "description": "Minimal residual disease assessed using serial blood samples. Tumor DNA was extracted and analyzed using the Adaptive ClonoSEQ Clinical Laboratory Improvement Amendments-regulated laboratory-developed test to determine DLBCL clonotypes that could then be followed in serial plasma samples.",
          "timeFrame": "Serial assessments from baseline through treatment (approximately up to 2 years)"
        },
        {
          "measure": "Duration of response (DR)",
          "description": "Duration of response was analyzed using the Kaplan-Meier method for patients who achieved a complete response (CR) or partial response (PR).",
          "timeFrame": "From the time of first documented response until disease progression or death (approximately up to 2 years)"
        },
        {
          "measure": "Time to tumor response (TTR)",
          "description": "Time to tumor response was summarized using descriptive statistics for patients who achieved a response.",
          "timeFrame": "From randomization to first documented response (approximately up to 2 years)"
        },
        {
          "measure": "Disease control (DC)",
          "description": "Disease control defined as the sum of complete response (CR) + partial response (PR) + stable disease (SD). Disease control rate was summarized by frequency counts and percentages.",
          "timeFrame": "From randomization until disease progression or end of study (approximately up to 2 years)"
        },
        {
          "measure": "Progression-free survival (PFS)",
          "description": "Progression-free survival as assessed by the investigator per Lugano Response Classification criteria, analyzed using the Kaplan-Meier method.",
          "timeFrame": "From randomization until disease progression or death from any cause (approximately up to 2 years)"
        },
        {
          "measure": "Overall survival (OS)",
          "description": "Overall survival analyzed using the Kaplan-Meier method.",
          "timeFrame": "From randomization until death from any cause (approximately up to 2 years)"
        },
        {
          "measure": "Safety",
          "description": "Safety assessed by treatment-related adverse events (TRAEs) graded according to CTCAE version 4.03, summarized by system organ class, preferred term, and maximum grade during the on-treatment period.",
          "timeFrame": "From first dose of study treatment through 90 days after last dose (approximately up to 2 years)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n- Histologically confirmed diffuse large B-cell lymphoma (DLBCL)\n- Age at least 18 years\n- Relapsed/refractory disease following two or more and up to four lines of rituximab-based multiagent chemotherapy\n- Patients who were ineligible for intensive second-line chemotherapy must have received at least one prior rituximab-containing combination chemotherapy regimen\n- Patients previously treated with bendamustine must have experienced a response duration of â‰¥ 6 months\n- Documentation of baseline measurable disease with at least one bidimensional lesion with the longest diameter > 1.5 cm on a computerized tomography scan, which was fluorodeoxyglucose avid on positron emission tomography scan\n\nExclusion Criteria:\n- Active central nervous system lymphoma\n- Prior organ transplant including prior allogeneic stem cell transplant\n- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-4-1BB (anti-CD137), or anti-CTLA-4 antibody (including ipilimumab and tremelimumab or any other antibody or drug specifically targeting T-cell costimulatory or immune checkpoint pathways)\n- Use of any standard or experimental anticancer therapy within 2 weeks prior to the first dose of study treatment, including cytoreductive therapy and radiotherapy, immunotherapy, or cytokine therapy (except for erythropoietin)\n- Use of any nondrug anticancer therapy (including CAR T-cell therapy)",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "N/A",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    }
  }
}